$647 Million is the total value of Cormorant Asset Management, LP's 71 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 15.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RCPT | Sell | RECEPTOS INC | $64,359,000 | -18.1% | 390,312 | -39.2% | 9.95% | -18.0% |
| ALKS | Buy | ALKERMES PLC | $42,679,000 | +62.0% | 700,000 | +55.6% | 6.60% | +62.3% |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $39,501,000 | -5.1% | 167,300 | -24.0% | 6.10% | -4.9% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $30,014,000 | +384.1% | 716,500 | +79.1% | 4.64% | +385.1% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $29,606,000 | +100.6% | 459,000 | +83.6% | 4.58% | +101.0% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $28,548,000 | +27.8% | 718,900 | -28.1% | 4.41% | +28.1% |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INC | $21,808,000 | +28.3% | 574,500 | -4.2% | 3.37% | +28.6% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $19,108,000 | +8.4% | 1,652,912 | -5.5% | 2.95% | +8.7% |
| DYAX | Sell | DYAX CORP | $19,082,000 | -9.5% | 1,138,900 | -24.1% | 2.95% | -9.3% |
| QTNT | Buy | QUOTIENT LTD | $19,025,000 | -3.9% | 1,119,100 | +1.7% | 2.94% | -3.7% |
| HRTX | Buy | HERON THERAPEUTICS INC | $18,479,000 | +162.4% | 1,270,000 | +81.4% | 2.86% | +163.0% |
| OVAS | Sell | OVASCIENCE INC | $16,070,000 | -51.4% | 462,720 | -38.1% | 2.48% | -51.3% |
| RGLS | Sell | REGULUS THERAPEUTICS INC | $15,187,000 | -13.9% | 896,522 | -18.5% | 2.35% | -13.7% |
| ADXS | Buy | ADVAXIS INC | $14,084,000 | +109.5% | 975,375 | +16.2% | 2.18% | +109.8% |
| ARDX | Sell | ARDELYX INC | $13,270,000 | -33.3% | 1,013,785 | -3.8% | 2.05% | -33.2% |
| TSRO | Sell | TESARO INC | $10,978,000 | -1.6% | 191,250 | -36.2% | 1.70% | -1.4% |
| KERX | Sell | KERYX BIOPHARMACEUTICALS INC | $10,515,000 | -25.7% | 826,000 | -17.4% | 1.62% | -25.5% |
| NVAX | Sell | NOVAVAX INC | $10,241,000 | +15.1% | 1,238,300 | -17.4% | 1.58% | +15.4% |
| DXCM | Sell | DEXCOM INC | $9,538,000 | -13.4% | 153,000 | -23.5% | 1.47% | -13.2% |
| KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $9,213,000 | -36.1% | 300,987 | -21.8% | 1.42% | -35.9% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $9,162,000 | +26.0% | 317,475 | +27.0% | 1.42% | +26.3% |
| CMRX | Sell | CHIMERIX INC | $8,650,000 | -46.3% | 229,500 | -42.6% | 1.34% | -46.2% |
| OMER | Sell | OMEROS CORP | $8,559,000 | -40.7% | 388,500 | -33.3% | 1.32% | -40.5% |
| EPRSQ | Buy | EPIRUS BIOPHARMACEUTICALS IN | $8,025,000 | +1788.2% | 896,600 | +1095.5% | 1.24% | +1778.8% |
| PFNX | New | PFENEX INC | $7,570,000 | – | 474,900 | +100.0% | 1.17% | – |
| CBPO | Sell | CHINA BIOLOGIC PRODS INC | $7,307,000 | +20.8% | 76,500 | -15.0% | 1.13% | +21.0% |
| AGEN | Buy | AGENUS INC | $7,228,000 | +127.6% | 1,409,000 | +76.1% | 1.12% | +128.0% |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $7,222,000 | +131.1% | 255,000 | +70.0% | 1.12% | +131.5% |
| SGMO | Sell | SANGAMO BIOSCIENCES INC | $6,931,000 | -8.9% | 442,000 | -11.6% | 1.07% | -8.7% |
| CHRS | Sell | COHERUS BIOSCIENCES INC | $6,701,000 | +84.8% | 219,130 | -1.4% | 1.04% | +85.3% |
| XLRN | Sell | ACCELERON PHARMA INC | $6,470,000 | -33.6% | 170,000 | -32.0% | 1.00% | -33.4% |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL INC | $6,333,000 | +20.3% | 102,000 | -15.0% | 0.98% | +20.6% |
| CRIS | Buy | CURIS INC | $6,317,000 | +601.9% | 2,632,000 | +338.7% | 0.98% | +602.2% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $6,265,000 | +32.5% | 850,000 | -15.0% | 0.97% | +32.8% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $6,140,000 | -36.9% | 680,000 | -15.0% | 0.95% | -36.7% |
| REPH | Sell | RECRO PHARMA INC | $5,949,000 | +197.2% | 655,907 | -6.3% | 0.92% | +197.4% |
| Sell | APTOSE BIOSCIENCES INC | $5,825,000 | -9.0% | 1,081,867 | -0.1% | 0.90% | -8.8% | |
| KITE | Sell | KITE PHARMA INC | $5,768,000 | -60.8% | 100,000 | -60.8% | 0.89% | -60.7% |
| NERV | Buy | MINERVA NEUROSCIENCES INC | $5,725,000 | +443.2% | 1,145,043 | +554.3% | 0.88% | +442.9% |
| LBIO | New | LION BIOTECHNOLOGIES INC | $5,145,000 | – | 424,815 | +100.0% | 0.80% | – |
| EPZM | New | EPIZYME INC | $5,000,000 | – | 266,250 | +100.0% | 0.77% | – |
| LPCN | New | LIPOCINE INC NEW | $4,600,000 | – | 666,666 | +100.0% | 0.71% | – |
| NKTR | Sell | NEKTAR THERAPEUTICS | $4,373,000 | -37.3% | 397,500 | -11.7% | 0.68% | -37.2% |
| GEVA | Sell | SYNAGEVA BIOPHARMA CORP | $4,145,000 | -55.3% | 42,500 | -57.5% | 0.64% | -55.2% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $4,085,000 | +24.0% | 170,000 | -15.0% | 0.63% | +24.2% |
| GLYC | Sell | GLYCOMIMETICS INC | $3,819,000 | +12.3% | 458,955 | -2.8% | 0.59% | +12.6% |
| GNVC | Sell | GENVEC INC | $3,725,000 | +34.7% | 1,262,835 | -5.0% | 0.58% | +35.2% |
| RMTI | Sell | ROCKWELL MED INC | $3,716,000 | -9.6% | 340,000 | -15.0% | 0.57% | -9.5% |
| CERU | Sell | CERULEAN PHARMA INCnew | $3,616,000 | +29.2% | 401,354 | -10.8% | 0.56% | +29.4% |
| ACRX | Sell | ACELRX PHARMACEUTICALS INC | $3,281,000 | -51.2% | 850,000 | -15.0% | 0.51% | -51.2% |
| VSAR | Sell | VERSARTIS INC | $3,123,000 | -30.4% | 170,000 | -15.0% | 0.48% | -30.2% |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $2,802,000 | -33.0% | 275,000 | -8.3% | 0.43% | -32.8% |
| DERM | Sell | DERMIRA INC | $2,610,000 | -27.9% | 170,000 | -15.0% | 0.40% | -27.9% |
| IMDZ | Sell | IMMUNE DESIGN CORP | $2,512,000 | -41.7% | 119,000 | -15.0% | 0.39% | -41.6% |
| KIN | Sell | KINDRED BIOSCIENCES INC | $2,345,000 | -10.1% | 328,497 | -6.1% | 0.36% | -10.0% |
| AQXP | Sell | AQUINOX PHARMACEUTICALS INC | $2,301,000 | +2.3% | 279,900 | -6.7% | 0.36% | +2.6% |
| AGRX | Buy | AGILE THERAPEUTICS INC | $1,688,000 | +83.3% | 182,053 | +21.4% | 0.26% | +83.8% |
| CLRB | CELLECTAR BIOSCIENCES INC | $1,648,000 | +0.6% | 530,000 | 0.0% | 0.26% | +0.8% | |
| BLCM | Sell | BELLICUM PHARMACEUTICALS INC | $1,182,000 | -14.5% | 51,000 | -15.0% | 0.18% | -14.1% |
| AKBA | Sell | AKEBIA THERAPEUTICS INC | $1,114,000 | -18.9% | 100,300 | -15.0% | 0.17% | -18.9% |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $1,067,000 | – | 61,500 | +100.0% | 0.16% | – |
| VCYT | Buy | VERACYTE INC | $984,000 | +1.7% | 135,190 | +34.9% | 0.15% | +2.0% |
| GALT | Sell | GALECTIN THERAPEUTICS INC | $959,000 | -11.4% | 286,200 | -8.3% | 0.15% | -11.4% |
| CLLS | New | CELLECTIS S Asponsored ads | $865,000 | – | 25,000 | +100.0% | 0.13% | – |
| SCYX | Sell | SCYNEXIS INC | $825,000 | -17.3% | 99,366 | -0.6% | 0.13% | -17.5% |
| PTCT | Sell | PTC THERAPEUTICS INC | $517,000 | -0.2% | 8,500 | -15.0% | 0.08% | 0.0% |
| AGTC | Sell | APPLIED GENETIC TECHNOL CORP | $520,000 | -59.2% | 26,010 | -57.1% | 0.08% | -59.2% |
| CLRBW | CELLECTAR BIOSCIENCES INC*w exp 08/19/201 | $413,000 | -2.6% | 530,000 | 0.0% | 0.06% | -1.5% | |
| NVRO | Sell | NEVRO CORP | $407,000 | +5.2% | 8,500 | -15.0% | 0.06% | +5.0% |
| CLTX | Sell | CELSUS THERAPEUTICS PLCsponsored adr ne | $218,000 | -84.9% | 286,508 | -4.5% | 0.03% | -84.7% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $43,000 | +16.2% | 850 | -15.0% | 0.01% | +16.7% |
| AAVL | Exit | AVALANCHE BIOTECHNOLOGIES IN | $0 | – | -65,000 | -100.0% | -0.54% | – |
| Exit | LIPOCINE INC NEW | $0 | – | -666,666 | -100.0% | -0.54% | – | |
| Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -5,000 | -100.0% | -0.57% | – | |
| ASPX | Exit | AUSPEX PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.81% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -300,000 | -100.0% | -5.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.